115 related articles for article (PubMed ID: 3401246)
1. In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man.
Zysset T; Zeugin T; Küpfer A
Biochem Pharmacol; 1988 Aug; 37(16):3155-60. PubMed ID: 3401246
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of dextromethorphan O-demethylation in man.
Küpfer A; Schmid B; Pfaff G
Xenobiotica; 1986 May; 16(5):421-33. PubMed ID: 3739367
[TBL] [Abstract][Full Text] [Related]
3. Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes.
Kerry NL; Somogyi AA; Mikus G; Bochner F
Biochem Pharmacol; 1993 Feb; 45(4):833-9. PubMed ID: 8452558
[TBL] [Abstract][Full Text] [Related]
4. Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.
Al-Dabbagh SG; Idle JR; Smith RL
J Pharm Pharmacol; 1981 Mar; 33(3):161-4. PubMed ID: 6116757
[TBL] [Abstract][Full Text] [Related]
5. Dextromethorphan metabolism in rat: interstrain differences and the fate of individually administered oxidative metabolites.
Bochner F; Somogyi AA; Chen ZR
Xenobiotica; 1994 Jun; 24(6):543-52. PubMed ID: 7975720
[TBL] [Abstract][Full Text] [Related]
6. Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man.
Mortimer O; Lindström B; Laurell H; Bergman U; Rane A
Br J Clin Pharmacol; 1989 Feb; 27(2):223-7. PubMed ID: 2713216
[TBL] [Abstract][Full Text] [Related]
7. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.
Schmid B; Bircher J; Preisig R; Küpfer A
Clin Pharmacol Ther; 1985 Dec; 38(6):618-24. PubMed ID: 4064464
[TBL] [Abstract][Full Text] [Related]
8. Dextromethorphan metabolism in Jordanians: dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation.
Irshaid YM; al-Hadidi HF; Latif A; Awwadi F; al-Zoubi M; Rawashdeh NM
Eur J Drug Metab Pharmacokinet; 1996; 21(4):301-7. PubMed ID: 9074894
[TBL] [Abstract][Full Text] [Related]
9. Methoxyphenamine metabolism in rat models of human debrisoquine phenotypes.
Roy SD; Hawes EM; McKay G; Hubbard JW; Midha KK
Can J Physiol Pharmacol; 1985 Jul; 63(7):778-81. PubMed ID: 3876145
[TBL] [Abstract][Full Text] [Related]
10. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism.
Muralidharan G; Midha KK; McKay G; Hawes EM; Inaba T
Xenobiotica; 1989 Feb; 19(2):189-97. PubMed ID: 2786289
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis.
Henthorn TK; Benitez J; Avram MJ; Martinez C; Llerena A; Cobaleda J; Krejcie TC; Gibbons RD
Clin Pharmacol Ther; 1989 Mar; 45(3):328-33. PubMed ID: 2920506
[TBL] [Abstract][Full Text] [Related]
12. Codeine O-demethylation: rat strain differences and the effects of inhibitors.
Mikus G; Somogyi AA; Bochner F; Eichelbaum M
Biochem Pharmacol; 1991 Mar; 41(5):757-62. PubMed ID: 1998530
[TBL] [Abstract][Full Text] [Related]
13. Methoxyphenamine and dextromethorphan as safe probes for debrisoquine hydroxylation polymorphism.
Roy SD; Hawes EM; Hubbard JW; McKay G; Midha KK
Lancet; 1984 Dec; 2(8416):1393. PubMed ID: 6150386
[No Abstract] [Full Text] [Related]
14. Phenotypic differences in dextromethorphan metabolism.
Vetticaden SJ; Cabana BE; Prasad VK; Purich ED; Jonkman JH; de Zeeuw R; Ball L; Leeson LJ; Braun RL
Pharm Res; 1989 Jan; 6(1):13-9. PubMed ID: 2717511
[TBL] [Abstract][Full Text] [Related]
15. Polymorphic ochratoxin A hydroxylation in rat strains phenotyped as poor and extensive metabolizers of debrisoquine.
Castegnaro M; Bartsch H; Bereziat JC; Arvela P; Michelon J; Broussolle L
Xenobiotica; 1989 Feb; 19(2):225-30. PubMed ID: 2786290
[TBL] [Abstract][Full Text] [Related]
16. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children.
Evans WE; Relling MV; Petros WP; Meyer WH; Mirro J; Crom WR
Clin Pharmacol Ther; 1989 May; 45(5):568-73. PubMed ID: 2721111
[TBL] [Abstract][Full Text] [Related]
17. Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley and DA rats: comparison with in-vivo results.
Vincent-Viry M; Deshayes S; Mothe O; Siest G; Galteau MM
J Pharm Pharmacol; 1988 Oct; 40(10):695-700. PubMed ID: 2907535
[TBL] [Abstract][Full Text] [Related]
18. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism.
Küpfer A; Schmid B; Preisig R; Pfaff G
Lancet; 1984 Sep; 2(8401):517-8. PubMed ID: 6147572
[No Abstract] [Full Text] [Related]
19. Genetically determined oxidation capacity and the disposition of debrisoquine.
Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
[TBL] [Abstract][Full Text] [Related]
20. Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients.
Larrey D; Babany G; Tinel M; Freneaux E; Amouyal G; Habersetzer F; Letteron P; Pessayre D
Br J Clin Pharmacol; 1989 Sep; 28(3):297-304. PubMed ID: 2789923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
